Subtopic Deep Dive
Transthyretin Cardiac Amyloidosis Diagnosis
Research Guide
What is Transthyretin Cardiac Amyloidosis Diagnosis?
Transthyretin Cardiac Amyloidosis Diagnosis involves non-invasive imaging techniques including bone scintigraphy, echocardiography, and cardiovascular magnetic resonance to detect ATTR cardiac amyloidosis without biopsy.
Bone scintigraphy with 99mTc-PYP or DPD tracers differentiates ATTR from AL amyloidosis with high specificity (Gillmore et al., 2016; Bokhari et al., 2013). Echocardiography reveals apical sparing strain patterns, while CMR shows late gadolinium enhancement characteristic of amyloid infiltration (Fontana et al., 2015). Over 50 papers since 2013 validate these methods, with Gillmore et al. (2016) cited 1894 times establishing non-biopsy diagnosis.
Why It Matters
Non-invasive diagnosis enables early ATTR-CA detection, improving outcomes before heart failure progresses, as shown in tafamidis trials (Maurer et al., 2018, 2523 citations). Differentiating ATTR from AL guides therapy, avoiding chemotherapy in ATTR patients (Bokhari et al., 2013). Screening protocols identify ATTR-CM in heart failure clinics, reducing mortality (Witteles et al., 2019). Consensus guidelines standardize multimodality imaging for clinical use (Dorbala et al., 2019).
Key Research Challenges
Differentiating ATTR from AL
Echocardiography lacks specificity, requiring scintigraphy confirmation (Gillmore et al., 2016). 99mTc-PYP uptake grades distinguish types but need serum testing exclusion (Bokhari et al., 2013). False positives occur in aortic stenosis overlap (Nitsche et al., 2020).
Early Detection Limitations
ATTRwt often presents late in elderly males with preserved ejection fraction (González-López et al., 2017). Biomarkers lack sensitivity for preclinical stages (Witteles et al., 2019). Staging systems aid prognosis but not early diagnosis (Gillmore et al., 2017).
Imaging Standardization
Variable scintigraphy protocols across tracers hinder comparisons (Dorbala et al., 2019). CMR late gadolinium enhancement prognostic value requires sequence optimization (Fontana et al., 2015). Multimodality integration needs validated algorithms (Ando et al., 2013).
Essential Papers
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Matthew J. Maurer, Jeffrey H. Schwartz, Balarama Gundapaneni et al. · 2018 · New England Journal of Medicine · 2.5K citations
In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all-cause mortality and cardiovascular-related hospitalizations and reduced the decline in functio...
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Julian D. Gillmore, Matthew J. Maurer, Rodney H. Falk et al. · 2016 · Circulation · 1.9K citations
Background— Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal cardiomyopathy for which several promising therapies are in development. The diagnosis is frequently delayed or misse...
A new staging system for cardiac transthyretin amyloidosis
Julian D. Gillmore, Thibaud Damy, Marianna Fontana et al. · 2017 · European Heart Journal · 693 citations
This simple, universally applicable staging system stratifies patients with both ATTRwt and ATTRv amyloid cardiomyopathy into prognostic categories. It will be of value in the design of forthcoming...
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Yukio Ando, Teresa Coelho, John L. Berk et al. · 2013 · Orphanet Journal of Rare Diseases · 684 citations
<sup>99m</sup> Tc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses
Sabahat Bokhari, Adam Castaño, Ted Pozniakoff et al. · 2013 · Circulation Cardiovascular Imaging · 608 citations
Background— Differentiating immunoglobulin light-chain (AL) from transthyretin-related cardiac amyloidoses (ATTR) is imperative given implications for prognosis, therapy, and genetic counseling. We...
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
Marianna Fontana, Silvia Pica, Patricia Réant et al. · 2015 · Circulation · 587 citations
Background— The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac inv...
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging
Sharmila Dorbala, Yukio Ando, Sabahat Bokhari et al. · 2019 · Journal of Nuclear Cardiology · 452 citations
Reading Guide
Foundational Papers
Start with Gillmore et al. (2016) for non-biopsy criteria (1894 citations), then Bokhari et al. (2013) for PYP validation (608 citations), and Ando et al. (2013) guidelines (684 citations) to grasp diagnostic foundations.
Recent Advances
Study Dorbala et al. (2019) consensus on multimodality (452 citations), Witteles et al. (2019) screening (323 citations), and Nitsche et al. (2020) aortic stenosis overlap (338 citations) for current applications.
Core Methods
Core techniques: 99mTc-PYP/DPD scintigraphy (Perugini grade 0-3), echocardiography global longitudinal strain with apical sparing, CMR extracellular volume and LGE patterns.
How PapersFlow Helps You Research Transthyretin Cardiac Amyloidosis Diagnosis
Discover & Search
Research Agent uses searchPapers and exaSearch to find 250+ papers on '99mTc-PYP scintigraphy ATTR-CA', then citationGraph on Gillmore et al. (2016) reveals 1894 citations including Dorbala et al. (2019) consensus. findSimilarPapers expands to Bokhari et al. (2013) for differentiation validation.
Analyze & Verify
Analysis Agent applies readPaperContent to extract scintigraphy protocols from Bokhari et al. (2013), verifies claims with CoVe against Gillmore et al. (2016), and runs PythonAnalysis on GRADE-scored evidence for sensitivity/specificity meta-analysis from 10 papers.
Synthesize & Write
Synthesis Agent detects gaps in early ATTRwt screening via contradiction flagging between González-López et al. (2017) and Witteles et al. (2019); Writing Agent uses latexEditText, latexSyncCitations for 20-paper review, and latexCompile for diagnostic flowchart with exportMermaid.
Use Cases
"Compare 99mTc-PYP vs DPD scintigraphy sensitivity in ATTR-CA using Python meta-analysis"
Research Agent → searchPapers('scintigraphy ATTR-CA') → Analysis Agent → readPaperContent(Bokhari 2013, Hutt 2014) → runPythonAnalysis(pandas meta-analysis of AUC values) → CSV export of pooled sensitivity 95%.
"Draft LaTeX review on non-invasive ATTR-CA diagnosis guidelines"
Synthesis Agent → gap detection(Gillmore 2016, Dorbala 2019) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(15 papers) → latexCompile(PDF with tables) → researcher gets camera-ready manuscript.
"Find GitHub code for CMR amyloidosis image analysis"
Research Agent → searchPapers('CMR ATTR-CA segmentation') → paperExtractUrls(Fontana 2015) → paperFindGithubRepo → githubRepoInspect(DICOM processing scripts) → researcher gets trainable U-Net models.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ ATTR-CA imaging) → citationGraph → DeepScan(7-step verification with CoVe checkpoints on Gillmore 2016 protocols). Theorizer generates hypotheses on multimodal scoring from Fontana 2015 CMR + Bokhari 2013 scintigraphy integrations.
Frequently Asked Questions
What defines non-biopsy diagnosis of ATTR-CA?
Non-biopsy diagnosis requires grade 2-3 99mTc-bone tracer uptake on scintigraphy plus absence of monoclonal protein (Gillmore et al., 2016).
What are key imaging methods?
99mTc-PYP scintigraphy differentiates ATTR from AL (Bokhari et al., 2013); echocardiography shows apical sparing; CMR detects late gadolinium enhancement (Fontana et al., 2015).
What are seminal papers?
Gillmore et al. (2016, Circulation, 1894 citations) established non-biopsy criteria; Bokhari et al. (2013, 608 citations) validated PYP scintigraphy; Dorbala et al. (2019) provided multimodality consensus.
What open problems remain?
Standardizing tracers across regions; improving early ATTRwt detection beyond imaging; validating AI integration for strain/CMR fusion (Witteles et al., 2019; Nitsche et al., 2020).
Research Amyloidosis: Diagnosis, Treatment, Outcomes with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Transthyretin Cardiac Amyloidosis Diagnosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers